Therefore, macrophages may be recruited to melanomas upon MAPK inhibitor treatment, which allows for a relatively quick development of drug tolerance through IL-1 signaling activation and subsequent stimulation of fibroblasts. The gene discussed is IL1A; the disease is melanoma.